The Symptoms and Impact of Recurrent Focal Segmental Glomerulosclerosis in Kidney Transplant Recipients: A Conceptual Model of the Patient Experience.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Works matching AU English, Marci
Results: 7
1
2
Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause: Pooled Analysis of Three Randomized Phase 3 Studies.
- Published in:
- Advances in Therapy, 2025, v. 42, n. 2, p. 1147, doi. 10.1007/s12325-024-03073-8
- By:
- Publication type:
- Article
3
Neuropathic pain: A patient‐centred approach to measuring outcomes.
- Published in:
- Health Expectations, 2018, v. 21, n. 4, p. 774, doi. 10.1111/hex.12673
- By:
- Publication type:
- Article
4
Fezolinetant impact on health‐related quality of life for vasomotor symptoms due to the menopause: Pooled data from SKYLIGHT 1 and SKYLIGHT 2 randomised controlled trials.
- Published in:
- BJOG: An International Journal of Obstetrics & Gynaecology, 2024, v. 131, n. 9, p. 1296, doi. 10.1111/1471-0528.17773
- By:
- Publication type:
- Article
5
Correction to: Qualitative study: burden of menopause-associated vasomotor symptoms (VMS) and validation of PROMIS sleep disturbance and sleep-related impairment measures for assessment of VMS impact on sleep.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
6
Qualitative study: burden of menopause-associated vasomotor symptoms (VMS) and validation of PROMIS Sleep Disturbance and Sleep-Related Impairment measures for assessment of VMS impact on sleep.
- Published in:
- Journal of Patient-Reported Outcomes, 2021, v. 5, n. 1, p. 1, doi. 10.1186/s41687-021-00289-y
- By:
- Publication type:
- Article
7
Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2023, v. 108, n. 8, p. 1981, doi. 10.1210/clinem/dgad058
- By:
- Publication type:
- Article